Nitro Compound Active Ingredients TRIZ Cases

2,4-ds-PBN is combined with temozolomide to cross the blood-brain barrier and suppress resistant glioma growth, spread, and vascularization.

This case uses native starch with silica to stabilize propandiol mononitrate storage, supporting consistent dosage in feed premixes.

Compressed tablets combine 3-nitrooxypropanol with gluten to sustain active ingredient release, addressing rapid disintegration of current formulations.

A topical composition combining benzalkonium chloride, allantoin, and nitrofurazone accelerates equine wound healing while minimizing scarring.

Propolis-based medicated oil promotes faster wound closure while reducing infection risk from frequent dressing changes.

Diluted nitric acid nitration of alkanediols eliminates explosive reagents and organic solvents, enabling safe industrial-scale production.

17β-heterocyclyl-digitalis compounds stimulate SERCA2a and inhibit the Na,K-pump to enhance cardiac contractility.

Steroidal compound 3α-ethynyl-3β-hydroxy-5α-androstan-17-one oxime antagonizes GABAA receptors to promote wakefulness.

Sulfated polysaccharide fucoidan composition inhibits influenza virus entry and replication, reducing cytokine-induced respiratory complications.

DNA repair inhibitors block single-strand repair pathways in cancer cells.

A powderous formulation uses silica with average particle size ≤ 320 µm to retain 3-nitrooxypropanol.

Inhibiting PER1 and PER2 proteins reverses postnatal cell cycle withdrawal, enabling cardiac tissue repair in heart attack treatment.

Reduced nitrone compounds modulate oxidation reactions to clear dense breasts despite uric acid interference.

Delayed PARP inhibitor administration after liposomal irinotecan reduces peripheral toxicity while maintaining therapeutic efficacy.